CSIMarket
 


Pasithea Therapeutics Corp   (KTTA)
Other Ticker:  
 

Pasithea Therapeutics 's Quick Ratio

KTTA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 10.53 below Pasithea Therapeutics 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Quick Ratio than Pasithea Therapeutics in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 206 to 224.

Explain Quick Ratio?
How much Cash & cash equivalents KTTA´s has?
What are KTTA´s Current Liabilities?


KTTA Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 1.76 % 88.16 % 77.74 % -15.04 % -59.78 %
Y / Y Cash & cash equivalent Change -53.58 % -44.16 % -40.55 % -37.42 % 106.16 %
Quick Ratio MRQ 10.53 13 15.28 20.53 23.08
KTTA's Total Ranking # 224 # 206 # 224 # 129 # 158
Seq. Current Liabilities Change -9.22 % 5.22 % 21.24 % -12.12 % 67.85 %
Seq. Cash & cash equivalent Change -26.49 % -10.51 % -9.75 % -21.82 % -11.56 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 125
Overall Market # 224


Quick Ratio Statistics
High Average Low
45.7 22.7 4.5
(Mar 31 2022)   (Sep 30 2021)




Financial Statements
Pasithea Therapeutics 's Current Liabilities $ 2 Millions Visit KTTA's Balance sheet
Pasithea Therapeutics 's Cash & cash equivalent $ 20 Millions Visit KTTA's Balance sheet
Source of KTTA's Sales Visit KTTA's Sales by Geography


Cumulative Pasithea Therapeutics 's Quick Ratio

KTTA's Quick Ratio for the trailling 12 Months

KTTA Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 1.76 % 88.16 % 77.74 % -15.04 % -59.78 %
Y / Y Cash & cash equivalent TTM Growth -53.58 % -44.16 % -40.55 % -37.42 % 106.16 %
Quick Ratio TTM 14.6 17.71 23.59 30.78 32.64
Total Ranking TTM # 2976 # 2689 # 2748 # 2235 # 28
Seq. Current Liabilities TTM Growth -9.22 % 5.22 % 21.24 % -12.12 % 67.85 %
Seq. Cash & cash equivalent TTM Growth -26.49 % -10.51 % -9.75 % -21.82 % -11.56 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the III Quarter 2023 to $1.87 millions, cumulative Quick Ratio decreased to 14.6 below the Pasithea Therapeutics Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 468 other companies have achieved higher Quick Ratio than Pasithea Therapeutics . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2689 to 2976.

Explain Quick Ratio?
How much Cash & cash equivalents KTTA´s has?
What are KTTA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 469
Healthcare Sector # 943
Within the Market # 2976


trailing twelve months Quick Ratio Statistics
High Average Low
43.22 21.51 8.36
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Acasti Pharma Inc   19.33 $ 27.006  Millions$ 1.397  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions
Fulcrum Therapeutics Inc   18.27 $ 257.091  Millions$ 14.075  Millions
Stoke Therapeutics Inc   18.18 $ 214.718  Millions$ 11.811  Millions

Date modified: 2024-01-10T05:56:43+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com